Nomad Power Solutions (NMAD) vs Rein Therapeutics (RNTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nomad Power Solutions (NMAD) has outperformed Rein Therapeutics (RNTX) over the past year, losing 11.2% versus a loss of 44.7%. Over five years, NMAD leads with a -77.2% price change compared with -96.2% for RNTX. Nomad Power Solutions is the larger company by market cap ($69.5 million vs $67.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NMAD | RNTX |
|---|---|---|
| Share price | $4.31 | $0.7805 |
| Market cap | $69.47M | $67.33M |
| 1-day change | +1.05% | +1.46% |
| YTD return | +8.65% | -33.68% |
| 1-year return | -11.23% | -44.65% |
| 5-year return | -77.17% | -96.19% |
| EPS (TTM) | $-1.01 | $-1.68 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.38 | $2.18 |
| 52-week low | $2.36 | $0.694 |
| Distance from 52-week high | -48.51% | -64.20% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +668.74% |
| Average volume | 273.42K | 430.81K |
| Shares outstanding | 16.10M | 86.27M |
| Employees | — | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NMAD has outperformed RNTX by 33.4 percentage points over the past year.
About Nomad Power Solutions
NMAD stock →NOMAD Power Solutions, Inc. develops utility-scale mobile energy storage systems on providing transportable solutions.
Health Care · Biotechnology: Pharmaceutical Preparations
About Rein Therapeutics
RNTX stock →Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
NMAD vs RNTX FAQ
Which is bigger, Nomad Power Solutions or Rein Therapeutics?
Nomad Power Solutions (NMAD) is larger, with a market capitalization of $69.47M compared with $67.33M for Rein Therapeutics (RNTX).
Which stock has performed better over the past year, NMAD or RNTX?
NMAD returned -11.23% over the past 12 months, compared with -44.65% for RNTX (price return, excluding dividends). Past performance does not predict future results.
Are Nomad Power Solutions and Rein Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.